Danish (OMX) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 28 May 2026	DKK 1.7t	DKK 468.6b	DKK 147.0b	20.4x	11.7x	3.7x
Sat, 25 Apr 2026	DKK 1.6t	DKK 447.3b	DKK 129.9b	18.3x	12x	3.5x
Mon, 23 Mar 2026	DKK 1.5t	DKK 447.7b	DKK 130.0b	16.2x	11.2x	3.2x
Wed, 18 Feb 2026	DKK 1.8t	DKK 448.1b	DKK 134.9b	16.9x	13.5x	4.1x
Fri, 16 Jan 2026	DKK 2.1t	DKK 454.1b	DKK 137.0b	18.5x	15.6x	4.7x
Sun, 14 Dec 2025	DKK 1.9t	DKK 453.8b	DKK 136.9b	17.4x	14.1x	4.2x
Tue, 11 Nov 2025	DKK 1.8t	DKK 453.0b	DKK 135.7b	17.7x	13.3x	4x
Thu, 09 Oct 2025	DKK 2.2t	DKK 447.6b	DKK 141.8b	18.6x	15.7x	5x
Sat, 06 Sep 2025	DKK 2.0t	DKK 447.3b	DKK 141.7b	19.9x	14.5x	4.6x
Mon, 04 Aug 2025	DKK 1.8t	DKK 423.5b	DKK 124.6b	29.3x	14.6x	4.3x
Wed, 02 Jul 2025	DKK 2.4t	DKK 422.9b	DKK 124.4b	30.5x	19.3x	5.7x
Fri, 30 May 2025	DKK 2.5t	DKK 423.8b	DKK 124.7b	30.5x	19.9x	5.8x
Sun, 27 Apr 2025	DKK 2.3t	DKK 409.2b	DKK 121.3b	21.9x	18.6x	5.5x
Tue, 25 Mar 2025	DKK 2.8t	DKK 409.5b	DKK 121.3b	24.5x	23.1x	6.8x
Thu, 20 Feb 2025	DKK 3.2t	DKK 409.9b	DKK 121.5b	26.9x	26x	7.7x
Sat, 18 Jan 2025	DKK 3.1t	DKK 387.5b	DKK 111.3b	28.5x	27.9x	8x
Mon, 16 Dec 2024	DKK 3.9t	DKK 387.4b	DKK 111.3b	30.5x	34.9x	10x
Wed, 13 Nov 2024	DKK 3.9t	DKK 386.3b	DKK 110.7b	32.5x	35.2x	10.1x
Fri, 11 Oct 2024	DKK 4.1t	DKK 372.0b	DKK 107.1b	36.8x	38.6x	11.1x
Sun, 08 Sep 2024	DKK 4.5t	DKK 371.9b	DKK 107.2b	34.9x	42.2x	12.2x
Tue, 06 Aug 2024	DKK 4.3t	DKK 355.3b	DKK 106.3b	36.1x	40.9x	12.2x
Thu, 04 Jul 2024	DKK 4.9t	DKK 355.3b	DKK 106.2b	34.8x	45.8x	13.7x
Sat, 01 Jun 2024	DKK 4.7t	DKK 355.3b	DKK 106.2b	36.8x	44.1x	13.2x
Mon, 29 Apr 2024	DKK 4.5t	DKK 341.4b	DKK 99.6b	33.1x	45.3x	13.2x
Wed, 27 Mar 2024	DKK 4.6t	DKK 341.2b	DKK 99.6b	39.2x	45.8x	13.4x
Fri, 23 Feb 2024	DKK 4.4t	DKK 340.1b	DKK 98.9b	38x	44.4x	12.9x
Sun, 21 Jan 2024	DKK 3.8t	DKK 320.5b	DKK 90.0b	34.5x	42.1x	11.8x
Tue, 19 Dec 2023	DKK 3.5t	DKK 320.5b	DKK 90.0b	32.4x	38.7x	10.9x
Thu, 16 Nov 2023	DKK 3.5t	DKK 320.0b	DKK 90.1b	33x	38.9x	11x
Sat, 14 Oct 2023	DKK 3.7t	DKK 305.6b	DKK 82.2b	30.7x	45x	12.1x
Mon, 11 Sep 2023	DKK 3.6t	DKK 305.5b	DKK 82.2b	36.4x	43.4x	11.7x
Wed, 09 Aug 2023	DKK 3.4t	DKK 288.2b	DKK 74.9b	39.7x	45.3x	11.8x
Fri, 07 Jul 2023	DKK 3.0t	DKK 287.1b	DKK 75.5b	39.7x	39.2x	10.3x
Sun, 04 Jun 2023	DKK 3.0t	DKK 287.2b	DKK 75.5b	39.7x	39.6x	10.4x

Current Industry PE

Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 30.2x.

The 3-year average PS ratio of 8.7x is higher than the industry's current PS ratio of 3.6x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
Revenues for these companies have grown 18% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?


DK Market	0.40%
Healthcare	0.67%
Life Sciences	3.07%
Pharma	0.77%
Medical Equipment	0.21%
Biotech	0.14%
Healthcare Services	-1.75%
Healthtech	-2.42%

Industry PE

Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.2x.

Analysts are expecting annual earnings growth of 20.4%, which is higher than its past year's earnings growth of 0.3% per year.

Forecasted Growth

Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.

In contrast, the Life Sciences industry is expected to see its earnings decline by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
NOVO B Novo Nordisk	DKK 290.10	0.6% +DKK 7.5b	-36.1%	PE10.5x
ALK B ALK-Abelló	DKK 266.00	3.3% +DKK 1.9b	49.5%	PE46x
DEMANT Demant	DKK 246.00	3.0% +DKK 1.5b	-4.3%	PE21.9x
HLUN B H. Lundbeck	DKK 42.62	2.9% +DKK 1.2b	17.3%	PE11.3x
ZEAL Zealand Pharma	DKK 322.80	2.2% +DKK 494.6m	-28.8%	PE3.6x

Novo Nordisk Presents Results from the POSEIDON Real-World Evidence Study on Cardiovascular Inflammation in People with Cardiovascular Disease

Novo Nordisk presented new results from the landmark POSEIDON real-world evidence study at the 94th European Atherosclerosis Society Congress in Athens, Greece. The study showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease (CVD) despite current standard-of-care treatment. The study found that 2 in 5 people with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) had CV inflammation, which is associated with an increased risk of major CV events. A second POSEIDON analysis recently published in the European Journal of Heart Failure showed that two in five people with heart failure also have CV inflammation. In POSEIDON, CV inflammation was measured and defined by high-sensitivity C-reactive protein (hsCRP) levels =2 mg/L. hsCRP is the most commonly used and widely available blood test for measuring CV inflammation. These findings underscore a significant gap in current CV care. Even when people receive guideline-recommended treatments to control, e.g., cholesterol, blood pressure and blood sugar, inflammation-driven CV risk persists. The POSEIDON study represents one of the largest contemporary global assessments of CV inflammation prevalence in this high-risk population. POSEIDON enrolled 18,904 patients across 18 countries spanning Europe, North America, South America and Asia-Pacific between 2023 and 2025. Within the study, 13,475 patients had ASCVD, of whom 5,757 (42.7%) had CKD, while 11,809 patients had heart failure spanning across all types of heart failure (preserved, mildly reduced or reduced). Cardiovascular inflammation plays a central role in the development and progression of ASCVD. Multiple studies have shown that people with CV inflammation face an increased risk of major adverse cardiovascular events, including heart attack, stroke and CV death. Inflammation also contributes to CKD progression, and CKD itself may promote inflammation, creating a cycle that amplifies CV risk. It also plays a key role in heart failure, and it is common across all types of heart failure, particularly in people with obesity, kidney disease and other metabolic conditions. The growing recognition of the role of inflammation in cardiovascular disease is reflected in recent guidelines from the European Society of Cardiology (ESC), the American Heart Association (AHA), and the American College of Cardiology (ACC), which include elevated hsCRP as a risk-modifying biomarker to guide more intensive preventive initiatives. POSEIDON is a large, multinational, cross-sectional observational real-world evidence study designed to evaluate the prevalence and characteristics of high inflammatory risk (defined as hsCRP =2 mg/L) in patients with ASCVD, with and without CKD and/or heart failure. The study enrolled 18,904 patients across 18 countries between 2023 and 2025. Patients with recent infections, hospitalisations or unplanned medical visits were excluded to ensure that inflammatory markers reflected CV inflammation rather than acute conditions. Cardiovascular inflammation is increasingly recognised as a key driver of ASCVD and a major contributor to persistent cardiovascular risk in people receiving standard preventive therapies. It also plays a key role in heart failure, and it is common across all types of heart failure (preserved, mildly reduced or reduced), particularly in people with obesity, kidney disease and other metabolic conditions. hsCRP is the most widely available blood test and validated biomarker of CV inflammation. Levels of CV inflammation =2 mg/L are associated with increased risk of major adverse CV events, including heart attack, stroke and CV death. Despite standard of care management of traditional risk factors such as cholesterol, blood pressure and blood sugar, many people with ASCVD continue to face elevated CV risk driven in part by persistent inflammation. The same is true for people with any type of heart failure, where CV inflammation is associated with more severe symptoms and an increase in the overall CV risk.

Danish (OMX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Novo Nordisk Presents Results from the POSEIDON Real-World Evidence Study on Cardiovascular Inflammation in People with Cardiovascular Disease

H. Lundbeck A/S Receives Marketing Authorization for Vyepti (Eptinezumab) in South Korea for Preventive Treatment of Migraine

GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside

Demant Faces Regulatory Uncertainty as EU Mulls Separate AI and Medical Device Rules

First half 2026 earnings: EPS and revenues miss analyst expectations

ZEAL: Obesity Trial Progress And Pipeline Execution Will Support Future Upside

Consensus EPS estimates increase by 39%

Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings

EMBLA: Share Cancellations And Renewed Capital Authorisations Will Support Future Upside

New minor risk - Share price stability

ChemoMetec A/S, Annual General Meeting, Oct 08, 2026

First quarter 2026 earnings released

Alk-Abelló A/S Upgrades Earnings Guidance for the Full-Year 2026

High number of new and inexperienced directors

New minor risk - Financial data availability